Physician profile
Haley E Meier
NPI 1093002461
$8,674.51
in general payments reported to CMS, 2019-2025
25 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,117 · 2022: $1,336 · 2023: $2,532 · 2024: $2,064 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,632 · Education: $381 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.39 |
| Education | $380.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,229.68 | 2021-2025 | |
| Galderma Laboratories, L.P. | $940.62 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $769.95 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $749.95 | 2021-2025 | Tremfya, Simponi, Remicade |
| Novartis Pharmaceuticals Corporation | $683.87 | 2022-2025 | |
| Ucb, INC. | $481.52 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $405.35 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $347.35 | 2021-2025 | Dupixent, Libtayo |
| Allergan, INC. | $340.67 | 2021 | |
| Leo Pharma INC. | $302.78 | 2021-2025 | Anzupgo, Adbry |
| Pfizer INC. | $236.79 | 2021-2025 | |
| Lilly USA, LLC | $214.61 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $157.92 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $157.13 | 2025 | Vtama |
| Genzyme Corporation | $154.39 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.44 | 2021-2023 | Arazlo |
| Almirall LLC | $61.32 | 2021-2023 | Klisyri |
| Dermavant Sciences, INC. | $53.09 | 2024 | Vtama |
| Incyte Corporation | $49.64 | 2022-2024 | Opzelura |
| Vyne Pharmaceuticals INC. | $47.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.07 | 2023 | Sotyktu |
| Genentech USA, INC. | $45.17 | 2021-2022 | |
| Revance Therapeutics, INC. | $26.37 | 2024 | Daxxify |
| Botanix Sb INC | $20.35 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $19.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.